Ultragenyx Pharmaceutical Inc
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues: | ||
| Product sales | $62,489 | $44,229 |
| Royalty revenue | 46,344 | 4,882 |
| Collaboration and license | — | 51,385 |
| Total revenues | 108,833 | 100,496 |
| Operating expenses: | ||
| Cost of sales | 17,533 | 12,257 |
| Research and development | 178,487 | 165,698 |
| Selling, general and administrative | 78,160 | 76,646 |
| Total operating expenses | 274,180 | 254,601 |
| Loss from operations | (165,347) | (154,105) |
| Interest income | 8,824 | 6,290 |
| Change in fair value of equity investments | 3,746 | (334) |
| Non-cash interest expense on liabilities for sales of future royalties | (15,847) | (15,636) |
| Other income (expense) | (1,605) | 308 |
| Loss before income taxes | (170,229) | (163,477) |
| Provision for income taxes | (455) | (495) |
| Net loss | $(170,684) | $(163,972) |
| Net loss per share, basic and diluted | $(2.03) | $(2.33) |
| Shares used in computing net loss per share, basic and diluted | 84,286,292 | 70,368,478 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.